Key facts
- This page summarizes Jay R. Venkatesan's Form 4 filing for Serina Therapeutics, Inc. (SER).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Apr 2025, 16:03.
Jay R. Venkatesan - 08 Apr 2025 Form 4 Insider Report for Serina Therapeutics, Inc. (SER)
- Reporting relationship
- Director
- Issuer ticker
- SER
- Reported as of
- 08 Apr 2025
- Net transaction value
- +$500,000
- SEC form
- 4
- Accepted by SEC
- 10 Apr 2025, 16:03:12 UTC
- Prior SEC filing
- 13 Feb 2025
- Next SEC filing
- 20 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jay R. Venkatesan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jay R. Venkatesan filed Form 4 for Serina Therapeutics, Inc. (SER) on 10 Apr 2025.
Change
- Previous filing in this sequence was filed on 13 Feb 2025.
- Current net transaction value: +$500,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SER
transaction
Derivative
Series A Convertible Preferred Stock
Award
- Transaction value
- $500,000
- Shares
- +96,525
- Change %
- Price
- $5.18
- Shares after
- 96,525
- Date
- 08 Apr 2025
- Ownership
- The Jay Venkatesan Legacy Trust
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 96,525
- Exercise price
- $5.18
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.